
RBM Partnership Governance Review & Restructuring

Partner Briefing
09-10 November 2022

Agenda

- Impact of the RBM Partnership to End Malaria
- Opportunity for Governance Reform
- Governance Review and Restructuring Timeline
- Board Decision Points
- Discussion

The RBM Partnership has continuously adapted over its 20+ year history to bring the world closer to ending malaria

Between 2000 and 2020

50% reduction
in malaria deaths

10.6 million
lives saved


1.7 billion
malaria cases prevented



The RBM Partnership has helped countries navigate evolving challenges, including COVID-19, and helped mobilize historic funding for the fight against malaria




2022 has already been a busy year for the RBM Partnership



The RBM Partnership Board adopted decisions to strengthen representation of and accountability to our community

- The RBM Partnership Board initiated a governance review in May 2022 in response to growing calls for the partnership to reflect a changing global health landscape.
- The Board adopted four decisions at its meeting on October 25th to reorganize itself, enabling increased engagement with malaria-affected communities and other segments of the malaria community.
- The new Board will be put in place by Q2 2023
- While the Board transition is underway, the Secretariat and Partnership and will continue to execute on their responsibilities.

Governance restructuring has been a consultative process that will culminate by Q2 2023



Decision Points from the October 25th Board Meeting

1

New hybrid
Board
composition

2

Constituency
group
engagement &
Board member
nomination
process

3

Forming a
Transition
Oversight
Committee

4

Preparation of
updated
Bye-laws

Hybrid Board Composition & Constituency Representation

- The Board adopted a new hybrid Board structure, with a combination of representational constituency-based and independent seats.
- The hybrid structure is expected to allow the Board to leverage key perspectives from across the global malaria community while also ensuring the Board has access to expertise and independent voices.

Countries	Civil Society	Funders	Private Sector	Science & Innovation	UNOPS and WHO	Unaffiliated (potentially including Chair)
<i>Representational Capacity</i>						<i>Independent, Individual Capacity</i>

Hybrid Board Composition & Constituency Representation

- Allocation of seats will ensure proportional geographic, based on epidemiological burden and complexity, and sector representation on the Board.
- Across all constituency segments, existing organizations will be prioritized to act as support structures for facilitating representative nominations.
- Consultations with AU are ongoing to determine appropriate support structures for Africa.

Countries			Civil Society	Funders	Private Sector	Science & Innovation	UNOPS and WHO	Unaffiliated (potentially including Chair)
8 or 9			2	5	2	1	2	3
Africa 5 or 6 (AU and RECs)	Asia 2	LA 1						
<i>Representational Capacity</i>								<i>Independent, Individual Capacity</i>

Board Transition and Bye-Laws Adoption

- A Transition Oversight Committee (TOC) is being formed to oversee the process of transitioning to new governance structures.
- Under the guidance of the TOC, the Bye-Laws will be updated to reflect adopted changes.
- The TOC commits to frequent communications as constituency representation details unfold.

Looking ahead

- Governance review process
 - Updated Bye-laws will be considered at the next Board meeting at the end of November
 - Constituency groups will receive more information about Board seats and the nomination process in the coming weeks
 - Looking forward to welcoming a new Board in Q1/Q2 2023
- While the Board transition is underway, the Secretariat and Partnership will continue to execute on their responsibilities.

